A Clinico-Anatomical Study of Pleeha in Pleehodara Roga W.S.R. to Therapeutic Effect of Sharpunkha Kshara

University College of Ayurveda1 个研究点分布在 1 个国家目标入组 30 人开始时间: 2020年10月16日最近更新: 2020年12月8日

适应症

试验速览

阶段: 1/2 期
状态: 尚未招募
发起方
入组人数: 30
试验地点: 1
主要终点: Improvement in Subjective and Objective criteria.

研究概览研究设计入排标准结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

It is a Randomized ParallelGroup Clinical Trial of 30 Patients Which are Divided in 3 Groups. Each GroupConsist of 10 Patients. First Group Will be treated with Medicine Prescribed inOPD. Second Group Will be treated with Medicines Provide in OPD/IPD +Sharpunkha Kshara.Third Group Will Be Treated with Only Sharpunkha Kshara

研究设计

研究类型: Interventional
分配方式: Computer generated randomization
盲法: Not Applicable

入排标准

年龄范围: 20.00 Year(s) 至 60.00 Year(s)（—）
性别: All

入选标准

•Patients with the classical signs and symptoms of Pleehavridhi (splenomegaly).

排除标准

•Patients with other Systemic Diseases like Diabetes Mellitus, Malignancy, CHD, etc.
•HbsAg and HIV Positive Patients.

结局指标

主要结局

Improvement in Subjective and Objective criteria.

时间窗: 2 Weeks

次要结局

To find out the Efficay of Sharpunkha Kshara(1 month)

研究者

发起方

University College of Ayurveda

申办方类型

Government medical college

研究点 (1)

Loading locations...

相似试验

已完成

不适用

Study the Effect of Acupuncture on Migraine Patient Without Aura Via Functional Magnetic Resonance Imaging.Migraine Without Aura

NCT04636359Beijing University of Chinese Medicine30

已完成

2 期

Evaluation of Triphala and chlorhexidine mouthwash use in reducing tooth decay and gum problemsICD 10 - K05.1Chronic gingivitis

CTRI/2017/10/010155Dr Ketaki Bhor72

已完成

1 期

Study to Investigate Comparative Pharmacokinetics, Safety, Immunogenicity and Tolerability Between AVT80 and EntyvioHealthy Male and Female Subjects

NCT06732804Alvotech Swiss AG385

已完成

3 期

The Efficacy and Safety Study of Protoxin Versus Botox® in Subjects With Moderate to Severe Glabellar LinesGlabellar Frown Lines

NCT05364580Protox Inc.269

已完成

3 期

A Study on Efficacy, Safety and Immunogenicity of 9MW0311 in Postmenopausal Women With OsteoporosisPostmenopausal Women Osteoporosis

NCT06804590Mabwell (Shanghai) Bioscience Co., Ltd.280